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novel treatments for AHF is not going as smoothly as it might. I would
like to sketch what I believe are the ﬁve most tenacious problems con-
tributing to this state of affairs (see Table 1), and list some of the few
strategies which in my opinion are promising.
Theﬁrst pitfall is that the therapeutic ﬁeld of AHF is complicated: the
deﬁnition of the syndrome itself is not straightforward, with many
etiologies and various manifestations [4]. A comparison between the
two latest versions of the European Society of Cardiology guidelines
for treatment of heart failure (from 2008 and 2012, respectively) [5,6]
shows that the deﬁnition is still evolving: even nowadays some of the
typical symptoms and signs of heart failure are still considered non-
discriminating and therefore of limited diagnostic value [7]. As candidly
stated in the latest guidelines, the treatment of AHF “remains largelyThe development of drugs for acute heart failure (AHF) over the last
two decades has resembled a particularly scary roller coaster ride. I have
followed developments in this ﬁeld from the beginning of the nineties:
over twenty years of great enthusiasm, hard work, great expectations,
and, alas, many disappointments.
A search of the literature for clinical trials in AHF identiﬁes 25
medium-to-large double-blind trials (phases IIb and III) on new chem-
ical entities published after 2000 (Fig. 1). Some of the drugs under scru-
tiny are well known, others less so; some reached the market long ago,
some are still not approved. The reader will certainly recognize names
such as dopamine, istaroxime, milrinone, enoximone, levosimendan,
and omecamtiv mecarbil in the inotrope/inodilators group; cinaciguat,
clevidipine, tezosentan, nesiritide and serelaxine among the vasodila-
tors; and the diuretics tolvaptan and rolofylline.
Recently, promising data were disclosed which bring some hope
[1,2]. However, clear-cut results on a handful of new drugs are still
awaited for (see the large study NCT01870778 on the efﬁcacy, safety
and tolerability of serelaxin when added to standard therapy in AHF,
to be completed in June 2016), and the ﬁeld at the moment continues
to be characterized by paucity of evidence [3].and Ltd. Open access under CC BY-NC-From my position in the industry I feel that the development of
opinion-based with little good evidence to guide therapy” [6].
Secondly, the armamentarium of drugs used to keep patients alive
(and with as little permanent cardiac damage as possible) through the
acute phase of heart failure is limited, and among the hemodynamically
active i.v. drugs, certain families such as vasodilators, diuretics,
inotropes, and vasopressors, currently dominate the ﬁeld [8,9]. Many
of those agents are so inexpensive that whatever incremental improve-
ment a newcomer might possibly demonstrate would be offset (even
eclipsed) by a premium price (and incremental cost) that would be
difﬁcult to justify to payers who are more and more pressed by budget
limitations [10].
Thirdly, in recent times the pharmaceutical industry has experi-
enced a rising attrition rate, deﬁned as failure of the discovery, develop-
ment, registration and launch phases [11]. Pharmaceutical companies
have responded in variousways, including streamlining and ‘de-risking’
their research strategies — that is to say focusing on fewer therapeutic
ﬁelds and more limited objectives. Moreover it must be recognized
that even for ‘Big Pharma’ the R&D budget is not limitless. Cardiovascu-
lar product innovation in general is reported to be declining [12,13] and
other therapeutic areas may appear much less risky than a fragmented
ﬁeld such as AHF. In short, AHF does not appear a good prospect for
the emergence of block-buster drugs: [14] that in turn discourages the
sort of ambitious investment that might produce a breakthrough.
Fourthly, AHF is a life-threatening syndrome and all regulatory clin-
ical trials are targeted not only to the short-term relief of symptoms, but
to reduction in longer-term mortality. The barrier to new entrants is
thus set very high. Signiﬁcant and meaningful increases in survival are
difﬁcult to demonstrate if patients in the referent group receive the
full gamut of existing p.o. and i.v. drugs. As an example, it is worthmen-
tioning the REVIVE II study (levosimendan vs. placebo, each on top ofND license. 
Fig. 1. Latest clinical trials on drugs for acute heart failure. PubMed was searched for pa-
pers describing (((“acute heart failure” or “acutely decompensated heart failure”)) and
“clinical trial”) and (“2000/01/01” [date–publication]:“2014/01/01” [date–publication]).
The 113 articles found by this search strategy allowed to identify 25 medium-large sized
double-blind trials on new chemical entities (phases IIb and III). The acronyms of the trials
are marked as follows: (a) trials on tezosentan, (b) levosimendan, (c) nesiritide,
(d) tolvaptan, (e) milrinone, (f) enoximone, (g) rolofylline, (h) istaroxime, (i) clevidipine,
(j) SLV320, (k) cinaciguat, (l) serelaxine, (m) omecamtiv mecarbil, and (n) dopamine.
12 Editorialstandard of care, in patients hospitalized forworsening heart failure and
LV ejection fraction ≤35%) [15] in which 87% of the patients in the pla-
cebo arm vs 92% in the active drug arm improved their dyspnea over
5 days. Similarly, in themore recent RELAX-HF study (serelaxin vs. place-
bo in patients admitted to hospital for AHF,with SBP N 125 mm Hg) [16],
improvement in dyspnea (Likert scale) was reached by 26% of the pa-
tients in the placebo arm vs 27% in the active drug arm.
A corollary of this situation is that convincing regulatory studies
need to be both large and lengthy. The consequence of such lengthy de-
velopment is that patent life begins to be worryingly short and
business cases are less prone to show a return over investment.
Finally, clinical studies have been often– andwith some justiﬁcation –
criticized for not representing the full diversity of AHF patients encoun-
tered in the “real world”. Such questions, although old [17], have not
yet generated good answers, and this becomes an additional confounding
factor which may delay reception of new drugs into the market. More-
over, trials in emerging markets are becoming an issue. The need on
one hand for global quality standards in international big clinical trials
and on the other for locally arranged clinical trials to secure regulatory
approval in some big national markets cannot always be reconciledwith-
out additional considerable costs.
In this complicated business environment a handful of companies
still support innovative research and expensive clinical development
[18]. In order to attract and retain the support of investors it is crucial
for these companies to create expectations. Yet, as I have argued in
this Editorial, AHF is an arena where it is wrong (I would say both mor-
ally and commercially) to encourage expectations that are too high. I
hope not to be over-simplistic or unduly negative when I state that
there cannot be one cure-all drug for AHF. There can be no realistic
expectation of a blockbuster in such a multi-dimensional condition
and no defensible reason to encourage hopes that such a drug is just
around the corner. In the era of personalized therapieswe should search
for drugs targeted to sub-settings of AHF (e.g. cardiogenic shock, AHF
with low ejection fraction, or others), not for panaceas.
Striving after a magic bullet has been the downfall of much research
in the past. As an example levosimendan was developed as an inotrope
and meant to be used independent of the SBP value of the patient. Its
vasodilatory effect very soon became evident, however, and nowadays
its use is restricted to patients with SBP N100 mm Hg [15]. During theTable 1
The main problems in the development of novel treatments for AHF.
• The deﬁnition of AHF is still evolving. Typical symptoms and signs of heart failure are still
• No new families of drugs in sight.Many generic inotropes, vasodilators, and diuretics. Difﬁc
• Harsh competition for R&D ﬁnancing between therapy areas within pharmaceutical indus
• Rising costs of clinical trials. Need for long term mortality data. Difﬁculties in showing adv
• Risk of running clinical trials on populations which do not fully represent the real patientsprocessmuch fusswas created, much timewas lost, some opportunities
vanished. I hope the lessonwas learned: the newcomer drugs should be
developed bearing in mind the variety of manifestations of AHF.
Pharma industry seems to have, alas, surprisingly short memory. As
it regards Omecamtiv mecarbil, for example, it appears that the earlier
discussion on sarcomere-active drugs has been forgotten. Decades ago,
molecules which prolong the contractility transient were ditched
because potentially harmful in case of ischemic conditions [19].
Omecamtiv shares some of these characteristics [20] and the latest
clinical trial on this positive inotropic drug (ATOMIC-AHF) indeed
showed a sign (albeit only a non-signiﬁcant numerical unbalance)
of myocardial infarction [21]. It could be a play of chance, or it
could be somehow related to the sign of cardiac ischemia described
by a previous Phase II trial [22].
Is it time to be rethinking the strategy? I believe so, and I suggest
some possible solutions.
Pharmacogenetic targeting of drugs for heart failure has been advo-
cated recently as a development strategy and business solution which
would provide a blend of clinical, commercial and health-care cost ben-
eﬁts [23]. A concrete suggestion, which I fully endorse, was recently
made by the Forbes analyst David Shaywitz, with the observation that
“The explosion of sensors andmobile technologies, and of digital health
more generally has dramatically increased our ability to understand a
patient's experience of disease, providing the opportunity for continu-
ous versus episodic assessment, and understand phenotype at a far
more granular level” [24]. This could be a possible way for increasing
the possibility of success in the discovery and development of new
AHF drugs.
Another possible way would be to go beyond the “mega trial”, as
Collins and co-workers suggest [25], and move towards Bayesian adap-
tive trial design in acute heart failure syndromes. This approach is suited
for investigating heterogeneous conditions such as AHF and allows in-
vestigators to study multiple treatment approaches and therapies in
multiple patient phenotypes within a single trial, while maintaining a
reasonable sample size.
I would ﬁnally recommend that the scientiﬁc societies in the ﬁeld of
cardiology strengthen their discussionswith pharmaceutical companies
and identify new ways of cooperation for the early phases of discovery
and development. A good start was the decision of the Heart Failure
Association of the European Society of Cardiology to re-name the Basic
Science working group as “Committee on Translational Research” and
give it a new focus of promoting the development, application and
translation of basic science knowledge to clinically relevant questions
and targets in the ﬁeld of heart failure.Conﬂict of interest
The author was among the inventors of levosimendan, one of the
drugs cited in the editorial, and is currently employed by the company
which has the global rights for this drug.References
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